AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02861677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Study NCT01775930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
Study NCT02969980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
Study NCT01182727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salsalate
Description: Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
Study NCT04047381 — intervention group
Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
Study NCT01551303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Liquid metered-dose nasal spray, 30 IUs, administered once.
Study NCT01551303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched nasal spray placebo
Study NCT02690636 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: daily fractions, five fractions per week.
Study NCT02690636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: daily fractions, five fractions per week.
Study NCT00960349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cediranib
Description: Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
Study NCT00960349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
Study NCT00960349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: S-1
Description: Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Study NCT00960349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
Study NCT00960349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Study NCT02187575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX tablet
Study NCT02187575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX capsule
Study NCT01902212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Study NCT03959826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.
Study NCT03959826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.
Study NCT03959826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management for activity completion
Description: Participants will earn chances to win prizes for completing specific job-related activities.
Study NCT00756197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation Group 1
Description: Cryo Spray Ablation
Study NCT00756197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation Group 2
Description: cryo spray ablation
Study NCT01744002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder treatment and neck mobilization
Description: This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
Study NCT01744002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
Study NCT03194711 — intervention group
Intervention type: DEVICE
Intervention: BVS implantation
Description: BVS implantation using conventional semicompliant or non-compliant balloon
Study NCT01741506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin®)
Study NCT01741506 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dalteparin (Fragmin®)
Study NCT03673501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral KIT/PDGFRA kinase inhibitor
Study NCT03673501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Oral receptor tyrosine kinase (RTK) inhibitor
Study NCT03578146 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Rivaroxaban
Study NCT03578146 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Rivaroxaban
Study NCT03578146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00834730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N2O gas vs ketamine
Description: Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
Study NCT00834730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N2O gas vs ketamine
Description: Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
Study NCT02283736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus SP1
Description: Tablet containing Lactobacillus rhamnosus SP1
Study NCT02283736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Talc powder
Description: Tablet containing talc powder
Study NCT02283736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Scaling and root planning
Study NCT02283736 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal treatment
Description: Scaling and root planning
Study NCT03211143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: Test drug: CKD-381
Study NCT03211143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Reference drug: Nexium
Study NCT01685957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary treatment (STD)
Description: This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
Study NCT01685957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ned i vaegt (NIV)
Description: This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation.
Study NCT01685957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verdens bedste kur (VBK)
Description: This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals.
Study NCT01433068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBTXR3
Description: One intratumor implantation by injection
Study NCT04299048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: subcutaneous injection
Study NCT04527211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Oral administration of ivermectin 200 mcg/kg every week for seven weeks
Study NCT04527211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin
Description: Oral administration of ivermectin 200 mcg/kg every week for seven weeks
Study NCT00005711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma self-management education
Description: Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish.
Study NCT01432821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apomorphine (Experimental product)
Description: Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2
Study NCT01432821 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apomorphine (Experimental product)
Description: Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2
Study NCT04254107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-TGT
Description: Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
Study NCT04254107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
Study NCT04254107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given by IV on Day 1 of each 21-day cycle
Study NCT04185935 — intervention group
Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
Study NCT04185935 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01502137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
Study NCT01502137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
Study NCT01312714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 3 tablets of 1000 IU daily for 26 weeks
Study NCT01312714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets of 1000 IU daily for 26 weeks
Study NCT02824536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous Infusion of 3BNC117
Study NCT02824536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous Infusion of 10-1074
Study NCT02824536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion of Sterile Saline (NaCl 0.9%)
Study NCT00900640 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP as medically indicated by subjects referring physician
Description: Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
Study NCT03619759 — intervention group
Intervention type: DRUG
Intervention: Sugammadex
Description: Sugammadex injection as a reverse agent of neuromuscular blocking
Study NCT01625624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Food Bar
Description: Control Food Bar containing carbohydrate
Study NCT01625624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Carbohydrate Food Bar
Description: Test Food Bar containing modified carbohydrate
Study NCT02162992 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational
Study NCT02053428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous image-guided gastrostomy
Study NCT00245336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin
Description: 1000 U/mL applied topically in combination with absorbable gelatin sponge
Study NCT00245336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bovine thrombin
Description: 1000 U/mL applied topically in combination with absorbable gelatin sponge
Study NCT03877705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine ready tabs
Description: Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
Study NCT03877705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine ready tabs
Description: Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
Study NCT01898520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
Study NCT01898520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
Study NCT03558464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention (integrated package)
Description: During whole study (pregnant women and offspring):~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~* LNS (Enov' Mum, 20g sachet daily)~* Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~* MNP (MixMe, 1g sachet every three days)~* ORS + zinc~* 1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements).
Study NCT03900715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept
Study NCT04233333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: method of fixation of the orogastric tube
Description: Methods of fixation of the orogastric tube will be randomized
Study NCT04233333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: method of fixation of the orogastric tube
Description: Methods of fixation of the orogastric tube will be randomized
Study NCT01935193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lysine acetylsalicylate
Study NCT01151878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucomannan
Description: 1.26 g per sachet; 2 sachets per day for 4 weeks.
Study NCT01151878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: prepared in sachets (1.3g); 2 sachets per day for 4 weeks
Study NCT01802892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret 100 mg
Description: Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
Study NCT01802892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret 400 mg
Description: Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
Study NCT01802892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
Study NCT02602613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMEND Mitral Valve Repair System
Description: Annuloplasty ring applied in a transcatheter method
Study NCT04132089 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: capABILITY
Description: All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
Study NCT03204487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost 15µg/ml
Description: Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
Study NCT01043562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Defibrillator threshold testing
Description: Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.